Drug Profile
Research programme: influenza virus therapy - B&H Biotechnologies
Latest Information Update: 04 Aug 2016
Price :
$50
*
At a glance
- Originator B&H Biotechnologies
- Class Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 03 Aug 2016 Discontinued for Influenza virus infections (Treatment & Prevention) in USA (unspecified route)